Now Approved

COPIKTRA (duvelisib) is a prescription medicine used to treat adults with:

  • Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have received at least 2 prior therapies and they did not work or are no longer working.
  • Follicular Lymphoma (FL) who have received at least 2 prior therapies and they did not work or are no longer working.

This indication is approved under accelerated approval based on overall response rate (ORR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

It is not known if COPIKTRA is safe and effective in children less than 18 years of age.

  • TALK TO YOUR DOCTOR

    If you’ve been diagnosed with
    CLL/SLL or FL, ask your doctor if
    COPIKTRA is right for you.

  • STAY UP TO DATE

    Get the latest news
    and information
    about COPIKTRA.

  • LEARN ABOUT SUPPORT RESOURCES

    For information from our team,
    contact Verastem Cares.

WHAT IS COPIKTRA?

COPIKTRA is a prescription medicine used to treat adults with:

  • Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have received at least 2 prior therapies and they did not work or are no longer working.
  • Follicular Lymphoma (FL) who have received at least 2 prior therapies and they did not work or are no longer working.

This indication is approved under accelerated approval based on overall response rate (ORR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

It is not known if COPIKTRA is safe and effective in children less than 18 years of age.

What is the most important information I should know about COPIKTRA?

COPIKTRA can cause serious side effects, including:
  • Infections. Infections are common during COPIKTRA treatment and can be serious and can lead to death. Tell your healthcare provider right away if you have a fever, chills, or other signs of an infection during treatment with COPIKTRA.
  • Diarrhea or inflammation of your intestine. Diarrhea or inflammation of your intestine (colitis) is common during COPIKTRA treatment and can be serious and can lead to death. Your healthcare provider may prescribe an anti-diarrhea medicine for your diarrhea. Tell your healthcare provider right away if you have any new or worsening diarrhea, stool with mucus or blood, or if you have severe stomach-area (abdominal) pain. Your healthcare provider should prescribe medicine to help your diarrhea and check you at least weekly. If your diarrhea is severe or anti-diarrhea medicines did not work, you may need treatment with a steroid medicine.
  • Skin reactions. Rashes are common with COPIKTRA treatment. COPIKTRA can cause rashes and other skin reactions that can be serious and can lead to death. Tell your healthcare provider right away if you get a new or worsening skin rash, or other skin reactions during treatment with COPIKTRA, including:
    • painful sores or ulcers on your skin, lips, or in your mouth
    • severe rash with blisters or peeling skin
    • rash with itching
    • rash with fever

    Your healthcare provider may need to prescribe medicines, including a steroid medicine, to help treat your skin rash or other skin reactions.

  • Inflammation of the lungs. COPIKTRA can cause inflammation of your lungs which can be serious and can lead to death. Tell your healthcare provider right away if you get new or worsening cough or difficulty breathing. Your healthcare provider may do tests to check your lungs if you have breathing problems during treatment with COPIKTRA. Your healthcare provider may treat you with a steroid medicine if you develop inflammation of the lungs that is not due to an infection.

If you have any of the above serious side effects during treatment with COPIKTRA, your healthcare provider may stop your treatment for a period of time, change your dose of COPIKTRA, or completely stop your treatment with COPIKTRA.

Before taking COPIKTRA, tell your healthcare provider about all of your medical conditions, including if you:
  • have intestinal problems
  • have lung or breathing problems
  • have an infection
  • are pregnant or plan to become pregnant. COPIKTRA can harm your unborn baby.
    • Your healthcare provider should do a pregnancy test to see if you are pregnant before you start treatment with COPIKTRA.
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with COPIKTRA and for at least 1 month after the last dose of COPIKTRA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with COPIKTRA.
    • Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment with COPIKTRA and for at least 1 month after the last dose of COPIKTRA.
  • are breastfeeding or plan to breastfeed. It is not known if COPIKTRA passes into breast milk. Do not breastfeed during treatment and for at least 1 month after the last dose of COPIKTRA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. COPIKTRA and certain other medicines may affect each other.

COPIKTRA may cause serious side effects, including:
  • See “What is the most important information I should know about COPIKTRA?”
  • Elevated liver enzymes. COPIKTRA may cause abnormalities in liver blood tests. Your healthcare provider should do blood tests during your treatment with COPIKTRA to check for liver problems. Tell your healthcare provider right away if you get any symptoms of liver problems, including yellowing of your skin or the white part of your eyes (jaundice), pain in the abdominal region, bruising or bleeding more easily than normal.
  • Low white blood cell count (neutropenia). Neutropenia is common with COPIKTRA treatment and can sometimes be serious. Your healthcare provider should check your blood counts regularly during treatment with COPIKTRA. Tell your healthcare provider right away if you have a fever or any signs of infection during treatment with COPIKTRA.
Common side effects of COPIKTRA include:
  • tiredness
  • fever
  • cough
  • nausea
  • upper respiratory infection
  • bone and muscle pain
  • low red blood cell count
These are not all the possible side effects of taking COPIKTRA. Talk to your doctor if you experience these or any other symptoms.

How should I store COPIKTRA?
  • Store COPIKTRA at room temperature between 68°F to 77°F (20°C to 25°C).
  • Keep COPIKTRA in its original container until you are ready to take your dose.

Keep COPIKTRA and all medicines out of the reach of children.

Please see full Prescribing Information, including Boxed Warning and Medication Guide.

You are encouraged to report side effects of COPIKTRA (duvelisib) to Verastem Oncology at 1-877-7RXVSTM (1-877-779-8786)
or the FDA at MedWatch or at 1-800-FDA-1088.

Expand

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT COPIKTRA?

COPIKTRA can cause serious side effects, including:
  • Severe diarrhea. Diarrhea is common during COPIKTRA treatment and can sometimes be severe. Tell your doctor right away if the number of bowel movements you have in a day increases by 4 or more, or if diarrhea is accompanied by abdominal pain. Ask your doctor about medicines you can take to treat your diarrhea.